SCNX Scienture Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1382574 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY127.4%
TTM net income YoY-96.3%
TTM EPS YoY144.2%
Revenue 3-yr CAGR-24.9%
Net income 3-yr CAGR—
Margins
Gross margin78.5%
Operating margin-2,788.5%
Net margin-2,715.9%
FCF margin—
EBITDA margin-2,662.9%
Returns
ROE-57.1%
ROA-47.1%
ROIC (approx.)-47.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets32.6%
Debt / equity0.00x
Current ratio1.10x
Interest coverage-25.26x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-30.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $431,609 | $136,643 |
| Cost of revenue | $100,127 | $130,638 |
| Gross profit | $331,482 | $6,005 |
| R&D expense | $1.96M | $2.24M |
| SG&A expense | $7.93M | $6.68M |
| Operating income | -$42.59M | -$14.70M |
| Interest expense | $4.08M | $1.34M |
| Pretax income | -$43.51M | -$18.78M |
| Income tax | -$1.99M | -$534,396 |
| Net income | -$41.51M | $9.07M |
| EBITDA | -$42.10M | -$14.70M |
| EPS (basic) | -2.70 | 2.69 |
| EPS (diluted) | -2.70 | 2.48 |
| Weighted avg. shares (diluted) | 15.35M | 3.65M |
| Banking | ||
| Deposits | $1.18M | — |
| Balance sheet | ||
| Cash & equivalents | $6.66M | $308,096 |
| Receivables | $731,328 | $11,106 |
| Inventory | $213,408 | — |
| Current assets | $7.92M | $6.31M |
| PP&E, net | $15,500 | $17,500 |
| Goodwill | — | $21.37M |
| Intangibles | $70.97M | $76.40M |
| Total assets | $84.18M | $104.85M |
| Current liabilities | $2.74M | $7.91M |
| Long-term debt | — | $2.90M |
| Total debt | — | $2.90M |
| Total liabilities | $14.06M | $25.78M |
| Shareholders' equity | $70.12M | $79.07M |
| Net debt | — | $2.59M |
| Shares outstanding | 1.63M | 8.75M |
| Cash flow statement | ||
| Operating cash flow | -$13.38M | -$14.27M |
| Capital expenditure | — | $12,000 |
| Free cash flow | — | -$14.28M |
| Investing cash flow | — | $27.55M |
| Financing cash flow | $19.73M | -$12.98M |
| Depreciation & amortization | $491,781 | $2,000 |
| Stock-based compensation | $2.07M | $25,584 |
| Dividends paid | — | $14.86M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.